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Abstract
Purpose This study assessed the feasibility of implementing a novel model of integrated prostate cancer care involving an online
prostate cancer-specific holistic needs assessment (sHNA) and shared digital communication between patients and their
healthcare professionals (HCPs). The sHNA produces a semi-automated care plan that is finalised in consultation between the
patient and their practice nurse.
Methods Men living with and beyond prostate cancer were invited to participate in a 9-month non-randomised cluster controlled
feasibility study. The intervention group was asked to complete the sHNA on three occasions. Data were collected using Patient
Reported Outcome Measures (PROMs) at baseline, 10 and 24 weeks, and 9 months. Outcomes included recruitment, retention,
acceptability, and engagement with the sHNA and PROMs.
Results Fourteen general practices (8 intervention and 6 control), and 41men (29 intervention and 12 control) participated. Initial
patient engagement with the sHNAwas high, with all but one receiving practice nurse-led follow-up and an individualised care
plan. The sHNA proved useful in identifying ‘red flag’ symptoms, and helping practice nurses decide when to seek further
medical care for the patients. There was a high level of acceptability for patients and HCPs. However, integration of care did not
occur as intended because of problems linking hospital and general practice IT systems.
Conclusion While the study demonstrated the feasibility of implementing the sHNA, it did not meet the a priori progression
criteria; as such, undertaking a definitive randomised controlled trial is not appropriate until the identified methodological and
technical issues have been addressed.
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Introduction
Prostate cancer is the most common cancer in men living in
the UK, with over 47,000 cases diagnosed annually [1]. Ten-
year survival rates are high (84%), but cancer survivorship is
placing an increasing demand on already stretched specialist
services [1]. Consequently, many men living with or beyond
prostate cancer report on-going needs, with concerns around
urinary, bowel and sexual dysfunction, as well as general in-
formation [2]. Patient-perceived unmet needs have been
shown to be associated with decreased quality of life in cancer
survivors [3]. Changes to the organisation of services are re-
quired to ensure needs are more effectively addressed.
Primary care has traditionally had limited involvement in
comprehensive cancer care [4]. However, patients who are
stable or whose cancer has been successfully treated are in-
creasingly being offered primary care follow-up in line with
recommendations from the National Institute of Care
Excellence [5]. Guidance on follow-up for these patients,
however, has been very limited.
Integrated models of care have been proposed as a way
of optimising the treatment of cancer and follow-up care
[6]. However, primary and secondary care services are of-
ten fragmented; with poor communication, lack of coordi-
nation, and role definition indicated as persistent problems
[7]. Furthermore, patients living with and beyond cancer
often report a desire to be actively involved in their care,
but many feel excluded from care planning and shared
decision making [8].
Holistic needs assessments (HNA) are recommended in the
treatment and follow-up care for cancer and aim to provide a
mechanism to help patients more easily identify and disclose
their needs to healthcare professionals (HCPs), and aid the
development of person-centred care plans. The sharing of care
plans has been identified as a facilitator to improve commu-
nication and care coordination [8]. However, HNA are not
routinely carried out during follow-up for men with prostate
cancer.
Digital health technology has the potential to better enable
an integrated model of care via improvements in communica-
tion and information transfer [9]. When applied to the context
of HNA, digital health technology could facilitate the sharing
of identified needs and care plans, between services and with
the patient.
We developed an online prostate cancer-specific holistic
needs assessment (sHNA) [10] with the aim of promoting an
integrated approach to care through enhanced communication
between the patient and health care providers in specialist and
generalist settings. The sHNA includes 11 domains that en-
compass prostate cancer symptoms and a range of broader
issues. The system is adaptive, enabling patients to choose
domains for self-assessment that are deemed personally rele-
vant, and it also encompasses external links to curated sources
of information in response to specified concerns. In this way, it
is intended to support men in identifying and communicating
their on-going needs to their HCPs and to facilitate self-man-
agement. It also allows the online sharing of care plans be-
tween HCPs and the patient, thus promoting an integrated
approach to care through enhanced communication.
The aim of the current study was to test the feasibility of
undertaking a primary care-based randomized cluster con-
trolled trial in terms of recruitment, retention, engagement,
and acceptability of the intervention. This paper addresses
implementation (extent to which the intervention was deliv-
ered as intended), practicality (extent to which the intervention
was carried out with intended participants), and acceptability
(extent to which the intervention is deemed attractive to those
delivering it or programme recipients) [11].
Methods
Study design
This study is a non-randomised clustered controlled trial in-
volving two groups (intervention and control); the full proto-
col has been published previously [10]. Prior to study com-
mencement and due to delays in site opening, a substantial
amendment was approved to reduce the study duration from
12 to 9 months.
Participants
General practices (primary health care providers) were recruit-
ed in one area of the West Midlands, United Kingdom.
Practice eligibility was determined by a referral pathway to a
single specialist centre. Intervention sites were required to
support a practice nurse to partake in a training programme
run by Macmillan Cancer Support. This programme formed
part of a national roll out. The 5-day course included an intro-
duction to the biology and epidemiology of cancer, cancer
staging and grading, treatment types and treatment conse-
quences, impact on work, finances and relationships, commu-
nication skills, and support for the cancer patient. Nurses who
had previously undertaken the training were also eligible to
run the study. The study team provided an additional 2-day
prostate cancer specific programme held at the specialist cen-
tre for all the participating nurses.
Men were eligible to take part if they had ever received a
diagnosis of prostate cancer or treatment from the participat-
ing specialist service, were able to read, understand and com-
municate in English, and were able to provide informed writ-
ten consent. Men were excluded if they did not meet the
criteria, suffered from severe mental health problems, were
unable or unwilling to complete outcome assessments, and
were living in a care setting.
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Menwith prostate cancer were identified from practice lists
by practice administrators and screened for eligibility by their
general practitioner (GP). Eligible patients were sent postal
invitations along with relevant patient information materials
to consider, and were asked to return the expression of interest
reply slip. Eligible patients were also invited to take part on an
opportunistic basis during routine appointments. Written con-
sent from all participants was taken by a member of the study
team.
Ethics
This study was approved by the EastMidlands - Nottingham 2
Research Ethics Committee (REC reference: 15/EM/0534).
Procedures
Control
Participants at control practices received usual care which was
either provided by the specialist centre or by the general prac-
tice team depending on the individuals care pathway.
Intervention
Participants at intervention practices were offered the online
sHNA and practice nurse follow-up, described in detail else-
where [10]. They were invited to complete the sHNA at three-
time points (baseline, 3 months, and 6 months). Following
each completion, men were invited to make an appointment
with their nurse to discuss any concerns raised during the
assessment and to complete their personalised care plan.
Appointments were undertaken by telephone or face-to-face
at the patient’s practice. An indication of any serious or life-
threatening physical or psychological concerns produced a
‘red flag’ pop up advising the patient to contact their GP team
urgently.
Outcome measures
Feasibility and acceptability
A priori criteria for study feasibility and acceptability were as
follows:
& Recruitment: consent rate of ≥ 25% of eligible men pa-
tients approached about the study
& Engagement and follow-up data feasibility and acceptabil-
ity: ≥ 70% completion of the sHNA and outcome measure
by the intervention group at each time point.
& Intervention acceptability and usability were assessed
using an adapted version of a Technology Acceptance
Model (TAM) questionnaire and qualitative interviews.
Patient-reported outcome measures
PROMs were completed either online or on paper and
returned via the post and included Health-related Quality of
Life [The EuroQol five dimensions questionnaire (EQ5D)]
[12], Cancer Specific Quali ty of Life [European
Organisation for Research and Treatment of Cancer Quality
of Life Questionnaire (EORTC-QLQ)] [13], Prostate Cancer
Symptoms [Expanded Prostate Cancer Index Composite],
Cancer Survivor Unmet Needs [Cancer Survivors Unmet
Needs instrument] [14], mental well-being [The Warwick
and Edinburgh Mental Well-being Scale] [15], and Patient
Activation [Patient Activation Measure] [16]. Intervention
participants were also invited to complete an adapted version
of the Technology Assessment Model (TAM) at T4. All pa-
tient participants were asked to complete PROMs at baseline
(T1) and 9 months (T4). Interim assessments using a sub-set
of PROMs (Cancer Survivor Unmet Needs and Patient
Activation Measure) were conducted with the intervention
group at 10 weeks (T2) and 24 weeks (T3).
Sample size
As this was a feasibility study, no formal sample size calcula-
tion was undertaken. However, the sample size was deter-
mined on the basis of practice list sizes (range < 2000 to >
10,000) in the participating area with direct referral pathways
to the specialist site. It was estimated from population data that
a mean list size of 5000 patients would generate 30–40 men
with a diagnosis of prostate cancer. Thus, from our anticipated
ten intervention and four control practices, we predicted that
approximately 283 would fulfil eligibility, and that 85 men (~
30%)would consent.With an anticipated attrition rate of 20%,
we estimated study completion by approximately 68 patients,
49 intervention, and 19 control participants when allocated to
the available sites. An original sample size of 200 patients
(150 intervention and 50 control participants) was superseded
for the calculation above after list sizes were found to be
substantially smaller than the anticipated ~ 75 eligible patients
per practice.
Statistical analysis
Descriptive statistics were used to summarise baseline charac-
teristic data. Continuous variables were summarised as medi-
an [interquartile range (IQR)] and percentages were used for
categorical variables. Median change from baseline to post
intervention (at least 9 months) are reported for PROMs.
Missing data were handled using the SPSS default listwise
for each instrument. Significance testing was not carried out
owing to the fact that the study was not powered to detect
changes on any of the measures, low numbers, and high levels
of missing data.
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The adapted TAM was summarised using frequencies, and
web analytics were used to determine the percentage of pa-
tients engaging with each of the domains of the sHNA.
Results
Recruitment and retention
The flow of participants is highlighted in Fig. 1.
Recruitment of the 14 participating general practices (8 inter-
vention and 6 control) took place between February and
September 2017. Five nurses were recruited to the study and
undertook additional prostate cancer training. One nurse with-
drew prior to implementation. Of the remaining four, two were
regular practice nurses, and two were practice nurses with a dual
research role, asked to deliver the intervention at their own prac-
tice and others. Overall, 240 men were invited to participate,
with 41 (17%) subsequently recruited; 29 (21%) were at inter-
vention practices and 12 (13%) at controls. Recruitment rates
varied between practices from 10/12 eligible patients at one in-
tervention group practice to 1/27 in one control practice. Of those
allocated to the intervention group, 17 (59%) did not complete
the study (Fig. 1); however, four of these participants did agree to
complete follow-up assessments. Of those allocated to the con-
trol group, 1 (8%) did not complete.
Patient baseline characteristics, stratified by intervention
group, are shown in Table 1. Groups were generally well-
matched; however, the intervention group had a longer dura-
tion since diagnosis (65 vs 59 months) and a greater propor-
tion of participants over the age of 71 (76% vs 59%).
Retention rates were higher in the control group, with partic-
ipants in this group being less representative of men over the age
of 71 years, and more representative of those closer to point of
diagnosis when compared to the intervention group. Whilst this
might look to indicate a relationship between age and time since
diagnosis on retention, we deemed a between group analysis
inappropriate based on the small number of study participants.
However, for interest purposes only, we conducted further de-
scriptive analyses to investigate age and time since diagnosis on
the retention rates observed in the intervention group among
those who had the opportunity to complete the study (i.e. exclud-
ing the participants from the late starting site). Among study
completers, we observed no difference in terms of age between
older (71–85+ years) and younger (45–70 years) participantswith
retention being 50% for both groups. Median time since diagno-
sis was longer among study completers (120 vs 60 months).
Intervention implementation
Evidence of engagement and the implementation profile of the
intervention group is shown in Table 2. Implementation of the
Enrollment
Number of available practices in 
local CCG =66Number of practices eligible for 
intervention group (n= 20)
Number of practices eligible for 
control group (n= 46)
Practices allocated (non-
randomised)
n = 14
Practices allocated to intervention (n=8)
Participants screened n=169 
Non-eligible n=32
Participants invited n=137 
Participants recruited n=29 
Practices allocated to control n= 6
Participants screened n=124 
Non-eligible n=21 
Participants invited n=103 
Participants recruited n=12 
Allocation
Time Point 1: Completed sHNA 1 n= 22
Withdrew n = 6
Non-compliant with intervention but agreed to 
follow-up n=1
Time Point 2: Competed sHNA 2 = 20
Lapsed n=1 (agreed to follow-up)
Withdrawn n= 1
Time point 3: Competed sHNA 12
Lapsed (agreed to follow-up): n=2 
Died n=1
Lost to follow up- (late starting site) n=5
Follow-up 
Available for analysis n=16
Analysis  Available for analysis n=11
Withdrew n= 1
Fig. 1 Consort diagram to show participant flow through study
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intervention was relatively consistent with our implementa-
tion plan as described in the protocol [10]. Engagement was
assessed by sHNA completion rates, of which all but one were
followed-up with a nurse-led consultation and personalised
Table 1 Patient baseline
demographics stratified by group Intervention (n = 29) Control n = 12 Total (N = 41)
Time since primary diagnosis (months) 65 (48–129) 59 (50.25–120.5) 63 (49–127.5)
Age (n, %) years
45–50 0 (0) 0 (0) 0 (0)
51–55 1 (3) 1 (8) 2 (5)
56–60 0 (0) 0 (0) 0 (0)
61–65 4 (14) 1 (8) 5 (12)
66–70 2 (7) 3 (25) 5 (12)
71–75 8 (28) 1 (8) 9 (22)
76–80 7 (24) 2 (17) 9 (22)
81–58 7 (24) 2 (17) 9 (22)
85+ 0 (0) 2 (17) 2 (5)
Primary treatment (n, %)
Radical prostatectomy 10 (34) 4 (33) 14 (34)
Radiotherapy 8 (28) 0 (0) 8 (20)
Active surveillance 5 (17) 2 (17) 7 (17)
Hormones 4 (14) 1 (8) 5 (12)
Transurethral section of the prostate 1 (3) 1 (8) 2 (5)
Cystoprostatectomy 1 (3) 0 (0) 1 (2)
High intensity focal ultrasound 0 (0) 1 (8) 1 (2)
Unknown 0 (0) 3 (25) 3 (7)
Ethnicity (n, %)
White British 22 (76) 6 (50) 28 (68)
White Irish 2 (7) 0 (0) 2 (5)
Asian or Asian British Pakistani 1 (3) 0 (0) 1 (2)
Black or Black British African 0 (0) 1 (8) 1 (2)
Black or Black British Caribbean 2 (7) 0 (0) 2 (5)
Missing 2 (7) 5 (42) 7 (17)
Comorbidities (n, %)
Diabetes 7 (24) 3 (25) 10 (24)
CHD 3 (10) 1 (8) 4 (10)
Arthritis 6 (21) 4 (33) 10 (24)
COPD 4 (14) 2 (17) 6 (15)
CKD 4 (14) 3 (25) 7 (17)
Hypertension 8 (28) 4 (33) 12 (29)
Other cancer 5 (17) 1 (8) 6 (15)
Other 17 (59) 2 (17) 19 (46)
At least one comorbidity 23 (79) 10 (83) 33 (81)
Total number of comorbidities 2.5 (1–4.00) 1 (1–2.75) 2 (1–4)
Missing 1 (3) 0 (0) 1 (2.4)
Living arrangements (n, %)
With partner 20 (69) 9 (75) 29 (70)
With relatives 1 (3) 0 (0) 1 (2)
Alone 7 (24) 3 (25) 10 (24)
Missing 1 (3) 0 (0) 1 (2)
Caring responsibility (n, %) 2 (7) 0 (0) 2 (5)
Missing 1 (3) 0(0) 1 (2)
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care plan; reasons for this were due the patient’s admission to
hospital. The most common areas of concern indicated byweb
analytics reviewing domain access included ‘emotional and
psychological concerns’, ‘illness and treatment’, and ‘access
and services’. Consultations were predominately telephone-
based and lasted for a median of 15 min. As intended, the
sHNA highlighted symptoms of serious concern ‘red flags’
to both the patient and their HCPs, and based on sHNA out-
puts and nurse consultation, practice nurses made seven refer-
rals for men to receive more specialist care. Data on referrals
were not available for the control group.
Patient-reported outcome measures
Follow-up data were available for 16 intervention and 11 con-
trol participants. Table 3 displays completion rates at each
time point. Descriptive data stratified by group are presented
for PROMs completed at T1 and T4 (Table 4). Data for the
intervention group did not appear to denote a clear positive
change in the direction of improvement for any measures.
Acceptability
The adapted TAMwas returned by 11/29 participants. Results
indicate the sHNA to be acceptable, with areas of refinement
related to log on and password issues (Table 5). Only 2/5
practice nurses completed the measure, both indicating that
they would be ‘somewhat willing’ to use the sHNA routinely.
Discussion
The primary aim of our feasibility study was to assess the
recruitment, retention, acceptability, and engagement of pa-
tients and nurses with the sHNA.
Table 2 Implementation profile
for n = 29 participants allocated to
the intervention group
sHNA1 sHNA2 sHNA3
Participants completed HNA, n (%) 22 (76) 20 (69) 12 (41)
Participants receiving a nurse consultation (n) 21 20 12
Reasons for missed consultation
Poor health/ in hospital (n) 1
Consultation type
Telephone (n) 19 16 12
Surgery (n) 2 4 0
Length of consultation minutes
median (range) 15 (10–25) 15 (13–25) 15 (10–20)
Domains of sHNA accessed n (%)
Physical 8(28) 5(17) 4(14)
Emotional 17(59) 16(55) 14(48)
Illness treatment 10(34) 9(31) 8(28)
Information, Communication 9(31) 9(31) 1(3)
Independence 8(28) 9(31) 1(3)
Finance 6(21) 8(28) 0(0)
Occupational 7(24) 8(28) 4(14)
Rehabilitation 6(21) 5(17) 2(7)
Access and services 13(45) 9(31) 1(3)
Religious 7(24) 6(21) 4(14)
Legal 5(17) 5(17) 3(10)
Number of ‘red flags’ recorded
Physical 12 10 7
Emotional 0 1 0
Referrals n (%)
None 19 (90) 14(70) 11 (92)
GP 1 (5) 2 (10) 1(8)
Continence team 1(5) 0 (0) 0 (0)
Clinical nurse specialist 0 (0) 2 (10) 0 (0)
Missing 0 (0) 2 (10 0(0)
Reasons for missed sHNA are detailed in Fig. 1
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Initial patient engagement with the sHNAwas high, with all
but one patient receiving nurse-led follow-up and an
individualised care plan following the completion of the
sHNA. The sHNA also proved useful in identifying concerning
or ‘red flag’ symptoms for discussion, and helping practice
nurses decide when to seek or arrange further medical care for
the patients, thus contributing to important components of safe-
ty netting within primary care [17]. This coupled with positive
feedback indicated by the TAM suggests that online assess-
ments and joint care planning during nurse-led consultations
are acceptable to men living with and beyond prostate cancer.
However, care plans are often not routinely provided to cancer
patients [18]. Furthermore, it is widely reported that older adults
are underrepresented in cancer related-trials [19], yet ~ 50% of
men recruited to this study were over the age of 76 years.
Despite the positives that can be drawn from this, progression
criteria in terms of recruitment and engagement were not met.
Overall, patient recruitment was low for both the intervention
group (22%) and control group (13%) and lower than the 61%
recruitment of eligible men reported by a recent pilot study
looking at a nurse-led psycho-education intervention for men
with prostate cancer [20]. However, the mentioned study re-
cruited only participants who self-reported unmet needs related
to urinary, bowel, and sexual or hormone-related functioning/
vitality. In contrast, our study included both a digital element
and also a broader sample of men (i.e. those who had ever had a
prostate cancer diagnosis, regardless of the perceived level of
need). Whilst reasons for poor uptake were not recorded, a
recent systematic review reported that retention is lower among
cancer patients allocated to web-based intervention arms [21],
and thus such interventions may also achieve lower recruit-
ment. Difficulties engaging primary care practices to participate
in the study and the mandatory Macmillan training for the
nurses’ also impacted recruitment. Training dates were limited,
and some practice nurses were not able to attend, and as such
were not eligible to run an intervention site. Smaller than
anticipated practice patient lists also limited the numbers of
eligible participants.
Our descriptive analyses showed no difference between
older and younger participant groups in terms of retention.
However, the majority of men in the older age category
received additional support and encouragement from a
peer supporter ‘ITmate’ which likely enhanced their reten-
tion in the study. As such, the ITmate may represent a
promising model for improving recruitment and retention
rates among older adults for digital-based clinical trials.
Furthermore, we observed that median time since diagno-
sis was longer among study completers (120 vs 60 months),
but given the small number of participants other confound-
ing factors e.g. co-morbidities and disease severity were
not controlled for. As such, we make no inferences from
this. However, our previously published qualitative
study [22], concluded that the sHNA may be most relevant
if implemented at an early stage closer to diagnosis. As
such, time since diagnosis should be explored in a larger
trial, with tailored strategies for retention developed if this
factor is shown to be predictive of drop out.
Our findings demonstrate a potential for the sHNA to be
implemented as intended, with ~ 70% of intervention partici-
pants accessing sHNA 1 and 2. However, sHNA completion
rates failed to meet progression criteria, given the low number
of participants who completed sHNA 3. This was due to a
number of factors including a late starting site and cumulative
effects of study withdrawals and death. Most patients opted
for a telephone consultation rather than a face-to-face meeting
with the nurse, suggesting this as an acceptable and likely time
saving way to communicate. The median consultation length
was 15 min. Duration included time taken by the nurses to
open and log-in to the IT software, speak with the patient, and
update their care plan and records. Previous studies evaluating
specialist nurse-led telephone follow-up in men with prostate
cancer have shown high levels of satisfaction, with patients
Table 3 PROMs completion rates at each time-point
Intervention group Control group
Patient reported
outcome measures, n (%)
T1 T2 T3 T4 T1 T2 T3 T4
EPIC 19 (66) – – 9 (31) 9 (75) – – 5 (42)
*PAM 26 (90) 18 (62) 15 (52) 9 (31) 11 (92) – – 10 (83)
*CASUN 21 (72) 17 (59) 10 (34) 12 (41) 9 (75) – – 10 (83)
EQ-5D 26 (90) – – 11 (38) 11 (92) – – 10 (83)
WEMBWS 27 (93) – – 12 (41) 11 (92) – – 10 (83)
EORTC 13 (45) – – 6 (21) 8 (67) – – 8 (67)
T, time-point, EPIC (Expanded Prostate Cancer Index Composite); PAM (Patient Activation Measure); CASUN (Cancer Survivors’ Unmet Needs); EQ-
5D (The EuroQol five dimensions questionnaire);WEMWBS (Warwick-EdinburghMental Wellbeing Scale); EORTC-QLQ (European Organization for
Research and Treatment of Cancer Quality of Life Questionnaire)
*Indicates PROMs assessed as part of interim analysis at T2 and T3 (intervention only)
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finding the service both informative and useful [23]. Given the
increasing role of primary care in cancer care follow-up, it is
encouraging to see that telephone consultation remains a
favourable way of contact; as when coupled with novel digital
health technology as in our study, this has the potential to
improve intervention accessibility and reach [24].
Practice nursesmade seven patient referrals to other services.
Whilst it is unclear from the findings if these referrals were
above and beyond that of routine care, it does indicate a need
for this type of follow-up. The vast majority of needs identified
by patients through the sHNA were managed by the practice
nurse, highlighting the ability of this professional group to deal
with the broader concerns of men with prostate cancer and
coordinate their care. Interventions using nurse navigators have
previously been shown to improve patient experience and re-
duce problems in care for patients with breast, colorectal, and
lung cancer [25]. Using the sHNAoutcomes and patient clinical
information, nurses were able to determine any problems re-
quiring further management, and refer patients quickly and di-
rectly to a specialist nurse. Whilst this achieved coordination of
care, integration in terms of a shared approach to patient man-
agement did not take place. The major limiting factor to the
integration of care was a lack of integration between the IT
platform that held the sHNA output and the NHS Trust clinical
data management system. This necessitated a manual process
for alerting specialist clinicians to study patients with forthcom-
ing clinic appointments and required clinicians to register and
login to a website outside of their clinical portal. As a result, and
knowing practice nurses would be likely to make contact if
required, clinicians failed to access the system.
Emotional concern was the most common domain
accessed in the sHNA, suggesting that men seek greater sup-
port with emotional concerns. It is well evidenced that depres-
sion in men with prostate cancer is a significant and complex
issue [26]; however, whilst this study was not powered to
detect changes in outcomes, pre-and-post WEMWBS scores
did not denote a change of improvement for the intervention.
This suggests that sHNA and joint care-planning may not be
enough to support the emotional needs of men with prostate
cancer, but may help to identify men requiring emotional
support.
The sHNA was perceived as useful by patients, with
nurses’ indicating a willingness to implement it routinely.
However, these findings should be interpreted with caution
given the low patient numbers for the adjusted TAM.
Acceptability of the study protocol was low when considering
the high level of missing data within the PROMs. Reasons for
missing data are not known, but may be indicative of the high
volume of PROMs and resulting questionnaire fatigue.
Further work is required to ensure questionnaires are suitable
and acceptable to patients. This could include undertaking
cognitive interviews with patients to ensure acceptability of
the questionnaires [27], allowing for adaptions to be made
where indicated, as well as user testing to ensure acceptability
of the digital format they are presented in.
Limitations
The biggest limitation of this study was its inability to engage
general practices of sufficient size and lower than expected
Table 5 Patient acceptability of the technology
Strongly
disagree
Very much
disagree
Disagree Not sure Agree Very much
agree
Strongly
agree
Usefulness (n)
I would expect CHAT-P to help me improve my care 0 0 0 3 7 1 0
I would expect CHAT-P to be useful to the doctors
and nurses that care for me
0 0 0 1 10 0 0
I would expect CHAT-P to be useful in consultations 0 0 0 1 9 0 0
I expect using CHAT-P would help me to understand my condition 0 0 1 1 8 1 0
I expect CHAT-P to help me look after myself 0 0 0 4 5 2 0
Overall I expect CHAT-P to be of benefit to me 0 0 0 1 8 2 0
Ease of use (n)
I found it easy to log on to CHAT-P 0 1 3 2 2 2 0
I found it easy to re-set my password when required 0 1 4 0 4 0 0
I found the screen format clear 0 0 0 0 9 1 0
I was able to identify what needed to be filled in quite easily 0 0 0 1 6 2 1
I found it straight forward to interact with CHAT-P 0 0 0 2 5 3 0
I think the presentation of CHAT-P is good and has
a clear outline
0 0 1 2 6 1 0
I found the links to further information useful 0 0 0 3 5 2 0
Overall the system is easy to use 0 0 0 3 6 1 0
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rates of recruitment. This likely impacted on the way in which
the intervention was implemented as the sHNAwas designed
to help practice nurses embed cancer follow-up in the pathway
of prostate cancer. Practice nurses are in a unique situation
given their knowledge of the patient and their family to pro-
vide this additional follow-up support. However, research
nurses were unable to replicate this patient relationship in
practices that were not their own, likely impacting on recruit-
ment rates and potentially patient experience. Furthermore,
the extent to which the sHNA can be viewed as beneficial
(e.g. contributing to early specialist referrals) beyond that of
usual care is limited due to a lack of data collected from the
comparative group. Finally, attrition rates were higher than
expected, and poor completion of PROMs meant that limited
efficacy testing of the intervention to impact on important
factors associated with patient quality of life was not possible.
As the study did not meet progression criteria in terms of
recruitment, retention, or completion of outcome assessments,
we felt it inappropriate to undertake a power calculation to
determine a future study sample size. Instead, this study will
be used to refine our implementation strategy, with the refined
study design requiring further piloting prior to being tested in
a fully powered RCT.
The current Quality Outcomes Framework (QOF) (perfor-
mance management and payment of GPs in England)
incentivises primary care to establish a cancer register and con-
duct a cancer care review within 6 months of diagnosis [23].
However, there remains an unstandardized approach to cancer
follow-up. A lack of remuneration, rather than a lack of interest,
may explain the encountered difficulties with engaging practices
in the study, alongwith concerns recorded anecdotally regarding
the time required to implement the intervention.
Conclusion
In conclusion, although the findings from this feasibility study
failed to meet the progression criteria for undertaking a
randomised controlled trial in the current context of primary
care, the sHNAwas acceptable to patients and showed prom-
ise in facilitating focused and timely patient consultations,
identifying ‘red flag’ symptoms, and assisting with coordinat-
ed referrals to more specialist care. Furthermore, practice
nurses were open to implementing the sHNA into their routine
practice, but there may be a need for practices to be financially
incentivised to take on this activity. The findings of this study
underline known challenges to implementing digital technol-
ogy to facilitate care integration across healthcare services.
Whilst our study showed promise for improving care coordi-
nation, full integration did not occur as intended, and further
work is required to overcome barriers related to IT system
integration. However, with growing numbers of survivors,
the landscape of cancer is changing [28], and primary care
and specialist care communication is essential to ensuring
the long-term and optimal management of these patients.
With some small refinements to the sHNA together with IT
systems in place that can support integration across primary
and secondary care, there is clear potential for this system to
facilitate holistic integrated care.
Acknowledgements The authors would like to acknowledge the help and
support of Chameleon InformationManagement Services (CIMS) for the
building of sHNA, as well as the IT Services at our participating specialist
site for supporting the sHNA on their server. We would also like to show
our appreciation to Prof Sam H Ahmedzai, Prof Theodoros N Arvanitis,
Prof Prashant Patel, and Dr. Nisar Ahmed for their invaluable contribu-
tions to the early development of the study intervention and protocol.
Finally, we would like to thank the healthcare professionals from the
participating general practices and specialist care centre, our peer support-
er, and the patients who participated in the study.
Compliance with ethical standards
This study was approved by the East Midlands - Nottingham 2 Research
Ethics Committee (REC reference: 15/EM/0534). Written consent to par-
ticipate was obtained from all participants.
Conflict of interest This paper presents independent research funded by
the National Institute for Health Research (NIHR) under its Research for
Patient Benefit (RfPB) Programme (Grant Reference Number PB-PG -
0214-33092). The views expressed are those of the author(s) and not
necessarily those of the NHS, the NIHR or the Department of Health.
The funder was not involved with the design of the study, data collection,
analysis, interpretation of data, or in the writing of the manuscript. The
authors declare no other conflicts of interests.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. Cancer Research UK Cancer incidence for common cancers: Ten
most common cancers in males (2015). https:/ /www.
cancerresearchuk.org/health-professional/cancer-statistics/
incidence/common-cancers-compared#heading-One. Accessed 20
Jan 2019
2. Watson E, Shinkins B, Frith E, Neal D, Hamdy F, Walter F, Weller
D, Wilkinson C, Faithfull S, Wolstenholme J (2016) Symptoms,
unmet needs, psychological well-being and health status in survi-
vors of prostate cancer: implications for redesigning follow-up.
BJU Int 117(6B):E10–E19
3. Hansen DG, Larsen PV, Holm LV, Rottmann N, Bergholdt SH,
Søndergaard J (2013) Association between unmet needs and quality
of life of cancer patients: a population-based study. Acta Oncol
52(2):391–399
4. Mazza D, Mitchell G (2017) Cancer, ageing, multimorbidity and
primary care. Eur J Cancer Care 26(3):e12717
5. NICE National Institute for Health and Care Excellence (2014)
Prostate cancer: diagnosis and management. Clinical guideline
[CG175]. Accessed 11 February 2019
Support Care Cancer
6. Cortis L, Ward P, McKinnon R, Koczwara B (2017) Integrated care
in cancer: what is it, how is it used and where are the gaps? A
textual narrative literature synthesis. Eur J Cancer Care 26(4):
e12689
7. European CanCer Organisation (2017) Intergrated Cancer Care:
Bringing Primary Care and Secondary Care Together EECO
Position Statement. Accessed 11 Feb 2019
8. Lawn S, Fallon-Ferguson J, Koczwara B (2017) Shared care in-
volving cancer specialists and primary care providers–what do can-
cer survivors want? Health Expect 20(5):1081–1087
9. Garg S, Williams NL, Ip A, Dicker AP (2018) Clinical integration
of digital solutions in health care: an overview of the current land-
scape of digital technologies in cancer care. JCO Clin Cancer
Inform (2):1–9
10. Nanton V, Appleton R, Dale J, Roscoe J, Hamborg T, Ahmedzai
SH, Arvanitis TN, Badger D, James N, Mendelsohn R (2017)
Integrated Care in Prostate Cancer (ICARE-P): nonrandomized
controlled feasibility study of online holistic needs assessment,
linking the patient and the health care team. JMIR Res Protoc
6(7):e147
11. Bowen DJ, Kreuter M, Spring B, Cofta-Woerpel L, Linnan L,
Weiner D, Bakken S, Kaplan CP, Squiers L, Fabrizio C (2009)
How we design feasibility studies. Am J Prev Med 36(5):452–457
12. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D,
Bonsel G, Badia X (2011) Development and preliminary testing
of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life
Res 20(10):1727–1736
13. Groenvold M, Klee MC, Sprangers MA, Aaronson NK (1997)
Validation of the EORTC QLQ-C30 quality of life questionnaire
through combined qualitative and quantitative assessment of
patient-observer agreement. J Clin Epidemiol 50(4):441–450
14. Hodgkinson K, Butow P, Hunt G, Pendlebury S, Hobbs K, Lo SK,
Wain G (2007) The development and evaluation of a measure to
assess cancer survivors' unmet supportive care needs: the CaSUN
(Cancer Survivors’ unmet needs measure). Psycho-Oncology
16(9):796–804
15. Tennant R, Hiller L, Fishwick R, Platt S, Joseph S, Weich S,
Parkinson J, Secker J, Stewart-Brown S (2007) The Warwick-
Edinburgh mental well-being scale (WEMWBS): development
and UK validation. Health Qual Life Outcomes 5(1):63
16. Hibbard JH, Stockard J, Mahoney ER, Tusler M (2004)
Development of the patient activation measure (PAM): conceptu-
alizing and measuring activation in patients and consumers. Health
Serv Res 39(4p1):1005–1026
17. Jones D, Dunn L, Watt I, Macleod U (2019) Safety netting for
primary care: evidence from a literature review. Br J Gen Pract
69(678):e70–e79
18. Crawford-Williams F, March S, Goodwin BC, Ralph N, Galvao
DA, Newton RU, Chambers SK, Dunn J (2018) Interventions for
prostate cancer survivorship: a systematic review of reviews.
Psycho-Oncology 27(10):2339–2348
19. Ford JG, Howerton MW, Lai GY, Gary TL, Bolen S, Gibbons MC,
Tilburt J, Baffi C, Tanpitukpongse TP,Wilson RF (2008) Barriers to
recruiting underrepresented populations to cancer clinical trials: a
systematic review. Cancer 112(2):228–242
20. Watson EK, Shinkins B, Matheson L, Burns RM, Frith E, Neal D,
Hamdy F, Walter FM, Weller D, Wilkinson C (2018) Supporting
prostate cancer survivors in primary care: findings from a pilot trial
of a nurse-led psycho-educational intervention (PROSPECTIV).
Eur J Oncol Nurs 32:73–81
21. Corbett T, Singh K, Payne L, Bradbury K, Foster C, Watson E,
Richardson A, Little P, Yardley L (2018) Understanding acceptabil-
ity of and engagement with web-based interventions aiming to im-
prove quality of life in cancer survivors: a synthesis of current
research. Psycho-oncology 27(1):22–33
22. Clarke AL, Roscoe J, Appleton R, Dale J, Nanton V (2019 Dec)
“My gut feeling is we could do more...” a qualitative study explor-
ing staff and patient perspectives before and after the implementa-
tion of an online prostate cancer-specific holistic needs assessment.
BMC Health Serv Res 19(1):115
23. Casey R, Powell L, Braithwaite M, Booth C, Sizer B, Corr J (2017)
Nurse-led phone call follow-up clinics are effective for patients with
prostate cancer. JPE 4(3):114–120
24. Murray E, Hekler EB, AnderssonG, Collins LM,Doherty A, Hollis
C, Rivera DE, West R, Wyatt JC (2016) Evaluating digital health
interventions: key questions and approaches. Am J PrevMed 51(5):
843–851
25. Wagner EH, Ludman EJ, Bowles EJA, Penfold R, Reid RJ, Rutter
CM, Chubak J, McCorkle R (2014) Nurse navigators in early can-
cer care: a randomized, controlled trial. J Clin Oncol 32(1):12–18
26. Rice SM, Oliffe JL, Kelly MT, Cormie P, Chambers S,
Ogrodniczuk JS, Kealy D (2018) Depression and prostate cancer:
examining comorbidity and male-specific symptoms. Am J Mens
Health 12(6):1864–1872
27. Willis GB, Artino AR (2013) What do our respondents think We’re
asking? Using cognitive interviewing to improve medical education
surveys. Journal of Graduate Medical Education 5(3):353–356.
https://doi.org/10.4300/JGME-D-13-00154.1
28. Nekhlyudov L, Ganz PA, Arora NK, Rowland JH (2017) Going
beyond being lost in transition: a decade of progress in cancer
survivorship. J Clin Oncol 35 (18):1978
Publisher’s note Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.
Support Care Cancer
